Thyroid Pharmacology

Correct Answer

C — Levothyroxine

Rationale

Levothyroxine is synthetic thyroxine (T4) and is the standard preparation for thyroid hormone replacement. Liothyronine is synthetic triiodothyronine (T3), a different thyroid hormone preparation. Propylthiouracil and methimazole are thionamide antithyroid drugs that inhibit thyroid hormone synthesis — they are used to treat hyperthyroidism, not to replace thyroid hormone.

Correct Answer

A — Methimazole

Rationale

Methimazole is a thionamide antithyroid drug that inhibits thyroid peroxidase, blocking thyroid hormone synthesis. Propranolol is a non-selective beta-adrenergic receptor antagonist used as an adjunct in hyperthyroidism. Levothyroxine is a synthetic thyroid hormone replacement. Potassium iodide is an iodide preparation — a distinct pharmacological class from thionamides.

Correct Answer

B — Propylthiouracil

Rationale

Propylthiouracil is a thionamide antithyroid drug that inhibits thyroid peroxidase and, uniquely among thionamides, also inhibits type 1 deiodinase in peripheral tissues. Radioactive iodine (iodine-131) is an ablative radioisotope — a separate class. Propranolol is a beta-adrenergic receptor antagonist used as an adjunct. Dexamethasone is a glucocorticoid, not a thionamide.

Correct Answer

D — Propranolol

Rationale

Propranolol is a non-selective beta-adrenergic receptor antagonist, blocking both beta-1 and beta-2 receptors. Atenolol and metoprolol are cardioselective (beta-1 selective) beta-blockers — they are used as alternatives to propranolol in patients with reactive airway disease. Clonidine is an alpha-2 adrenergic receptor agonist, a completely different drug class.

Correct Answer

A — Liothyronine

Rationale

Liothyronine is synthetic triiodothyronine (T3). It has a shorter half-life of approximately one day compared with levothyroxine's 6–7 days and produces larger peak-to-trough hormone fluctuations. Levothyroxine is synthetic thyroxine (T4), a different thyroid hormone preparation. Methimazole and propylthiouracil are thionamide antithyroid drugs — they inhibit thyroid hormone synthesis rather than replacing it.

Correct Answer

C — Potassium iodide (saturated solution)

Rationale

Saturated solution of potassium iodide is an iodide preparation used to exploit the Wolff-Chaikoff effect and reduce thyroid gland vascularity, particularly before surgery or in thyroid storm. Cholestyramine is a bile acid sequestrant that also binds thyroid hormone in the gut but is classified separately. Propranolol is a beta-adrenergic receptor antagonist. Levothyroxine is a synthetic thyroid hormone replacement — none of these are iodide preparations.

Correct Answer

B — Elevated gastric pH impairs dissolution of standard levothyroxine tablets

Rationale

Standard levothyroxine tablets require an acidic gastric environment for dissolution and absorption. Proton pump inhibitors raise gastric pH by blocking parietal cell hydrogen ion secretion, impairing tablet dissolution and reducing levothyroxine bioavailability. The same mechanism explains reduced absorption with antacids and in patients with achlorhydria. Liquid levothyroxine formulations are minimally affected by gastric pH and are preferred when this interaction is clinically relevant. Proton pump inhibitors do not accelerate gut motility, directly bind levothyroxine, or induce hepatic enzymes.

Correct Answer

D — Inhibition of type 1 deiodinase in peripheral tissues, reducing thyroxine-to-triiodothyronine conversion

Rationale

Beyond their shared thyroid peroxidase inhibition, propylthiouracil uniquely inhibits type 1 deiodinase in peripheral tissues, reducing conversion of thyroxine to the more biologically potent triiodothyronine by approximately 40%. This peripheral action makes propylthiouracil the preferred thionamide in thyroid storm, where rapidly lowering circulating triiodothyronine is critical. Methimazole does not share this action. Neither drug blocks the sodium-iodide symporter, inhibits thyroid-stimulating hormone receptor signaling, or acts on type 2 deiodinase in the pituitary.

Correct Answer

A — Thionamides cause idiosyncratic immune-mediated destruction of granulocyte precursors, producing agranulocytosis

Rationale

Agranulocytosis is the most serious adverse effect of thionamides, occurring in 0.1–0.5% of patients through an idiosyncratic immune-mediated mechanism that destroys granulocyte precursors. It typically presents within the first 90 days as abrupt fever and pharyngitis. Because it cannot be predicted by routine blood count monitoring, patient education is the primary safeguard — patients must stop the drug immediately and seek urgent evaluation at the first sign of fever or sore throat. This is a class effect: agranulocytosis with one thionamide contraindicates use of the other.

Correct Answer

C — Levothyroxine's half-life of 6–7 days requires four to five half-lives to reach steady state after a dose change

Rationale

Levothyroxine has an elimination half-life of 6–7 days. After any dose change, four to five half-lives are needed to reach a new steady-state concentration — approximately 24–35 days, or roughly six weeks. Thyroid-stimulating hormone measured before steady state is reached reflects the transitional, not the new stable, thyroxine level and will not accurately guide dosing decisions. Rechecking too early risks unnecessary further dose adjustments. Levothyroxine bioavailability does not take six weeks to develop, and pituitary receptor upregulation is not the rate-limiting step.

Correct Answer

B — The thyroid stores a two to three month supply of preformed hormone in follicular colloid that continues to be secreted

Rationale

Thionamides block thyroid peroxidase and halt new hormone synthesis but cannot block secretion of hormone already stored as thyroglobulin in the follicular colloid. The thyroid gland normally maintains a two to three month reserve of preformed hormone. As this existing store depletes through ongoing secretion while new synthesis is blocked, circulating thyroid hormone levels fall gradually over two to four weeks. Beta-blockers are started simultaneously to control adrenergic symptoms during this lag period. Methimazole achieves intrathyroidal concentrations rapidly, and the delay has nothing to do with antibody clearance or receptor downregulation.

Correct Answer

A — Propranolol inhibits type 1 deiodinase at high doses, reducing peripheral conversion of thyroxine to triiodothyronine

Rationale

At high doses (80–160 mg per day), propranolol inhibits type 1 deiodinase in peripheral tissues, reducing thyroxine-to-triiodothyronine conversion by approximately 10–20%. Since triiodothyronine is the more biologically potent hormone, this reduction in peripheral conversion provides a pharmacodynamic advantage beyond simple adrenergic blockade — an advantage shared with propylthiouracil, which also inhibits type 1 deiodinase. Cardioselective agents like atenolol and metoprolol lack this additional action. Propranolol does not selectively block thyroid beta-2 receptors to reduce secretion.

Correct Answer

D — Rifampin induces hepatic cytochrome P450 enzymes and glucuronidation, accelerating thyroxine metabolism

Rationale

Rifampin is a potent inducer of hepatic cytochrome P450 enzymes and glucuronidation pathways that metabolize thyroxine. Accelerated thyroxine metabolism reduces circulating levothyroxine levels, causing the pituitary to sense hormone deficiency and increase thyroid-stimulating hormone secretion. Patients on rifampin typically require levothyroxine dose increases of 20–50% to maintain target thyroid-stimulating hormone. The same interaction occurs with phenytoin, carbamazepine, and phenobarbital. Rifampin does not bind levothyroxine in the gut, raise gastric pH, or inhibit type 1 deiodinase.

Correct Answer

C — Amiodarone inhibits type 1 deiodinase, impairing clearance of reverse triiodothyronine from circulation

Rationale

Type 1 deiodinase normally clears reverse triiodothyronine from circulation by converting it to inactive diiodothyronine. Amiodarone inhibits type 1 deiodinase, impairing this clearance pathway, causing reverse triiodothyronine to accumulate. The same type 1 deiodinase inhibition also reduces thyroxine-to-triiodothyronine conversion, explaining the low triiodothyronine and elevated free thyroxine seen with amiodarone use. These are pharmacological effects of the drug, not primary thyroid disease, and do not automatically require treatment. Amiodarone does not stimulate type 3 deiodinase, block the sodium-iodide symporter preferentially, or chemically convert triiodothyronine to its reverse form.

Correct Answer

B — Calcium carbonate binds levothyroxine in the gastrointestinal tract, reducing its absorption when taken simultaneously

Rationale

Calcium carbonate, ferrous sulfate, antacids, cholestyramine, and sucralfate all reduce levothyroxine absorption when co-administered by binding the drug in the gastrointestinal tract before it can be absorbed. The result is a functional reduction in delivered dose, causing thyroid-stimulating hormone to rise despite an unchanged prescription. The management principle is consistent across all such interactions: take levothyroxine on an empty stomach, at least 30–60 minutes before breakfast, separated from any potentially interacting agent by at least four hours. Calcium carbonate does not induce hepatic enzymes, affect peripheral thyroid hormone receptor binding, or act on pituitary thyroid-stimulating hormone secretion directly.

Correct Answer

D — Prolonged propylthiouracil use carries risk of idiosyncratic fulminant hepatic necrosis, making continued exposure beyond the first trimester unacceptable

Rationale

Propylthiouracil is preferred over methimazole in the first trimester specifically to avoid methimazole embryopathy during organogenesis. However, propylthiouracil carries a black-box warning for idiosyncratic fulminant hepatic necrosis — a risk that makes prolonged use beyond the period of methimazole teratogenicity unacceptable. Once organogenesis is complete and the embryopathy window has passed at approximately 16 weeks, the balance shifts: the ongoing hepatotoxicity risk of propylthiouracil outweighs its advantage, and therapy is switched to methimazole for the remainder of the pregnancy. The two drugs are equally effective at controlling Graves disease; efficacy is not the reason for the switch.

Correct Answer

A — Propylthiouracil inhibits type 1 deiodinase in peripheral tissues, rapidly reducing conversion of thyroxine to the more potent triiodothyronine

Rationale

In thyroid storm, reducing circulating triiodothyronine as rapidly as possible is critical because triiodothyronine drives the adrenergic hyperactivation and end-organ toxicity of the crisis. Propylthiouracil's inhibition of type 1 deiodinase reduces peripheral thyroxine-to-triiodothyronine conversion by approximately 40%, providing a pharmacodynamic advantage that methimazole lacks. Methimazole is approximately 10-fold more potent than propylthiouracil at inhibiting thyroid peroxidase on a milligram basis. Propylthiouracil does not block thyroid-stimulating hormone receptor antibodies and does not have a longer intrathyroidal half-life than methimazole.

Correct Answer

C — Methimazole is associated with embryopathy during organogenesis in weeks 6–10, while propylthiouracil carries lower teratogenic risk

Rationale

Methimazole use during organogenesis (approximately weeks 6–10 of gestation) is associated with a characteristic embryopathy including aplasia cutis, choanal atresia, and esophageal atresia. Propylthiouracil does not carry the same teratogenic risk during this period and is therefore preferred for first-trimester management. Both thionamides cross the placenta; propylthiouracil's lower placental transfer per milligram compared with methimazole also contributes to its first-trimester preference. At approximately 16 weeks, therapy is typically switched back to methimazole to avoid the risk of propylthiouracil-associated fulminant hepatotoxicity with prolonged use.